Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age

Yaprak Ece Yola Atalah; Hatice Ezgi Barış; Selda Küçük Akdere; Meltem Sabancı; Hülya Özdemir; Kıvılcım Gücüyener; Ela Erdem Eralp; Eren Özek; Perran Boran

doi:10.5664/jcsm.10760

Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age

J Clin Sleep Med. 2023 Dec 1;19(12):2075-2085. doi: 10.5664/jcsm.10760.

Authors

Yaprak Ece Yola Atalah¹, Hatice Ezgi Barış¹, Selda Küçük Akdere¹, Meltem Sabancı², Hülya Özdemir³, Kıvılcım Gücüyener⁴, Ela Erdem Eralp⁵, Eren Özek³, Perran Boran¹

Affiliations

¹ Marmara University, School of Medicine, Department of Pediatrics, Division of Social Pediatrics, Istanbul, Turkey.
² Marmara University, School of Medicine, Child Sleep Laboratory, Istanbul, Turkey.
³ Marmara University, School of Medicine, Department of Pediatrics, Division of Neonatology, Istanbul, Turkey.
⁴ Gazi University, School of Medicine, Division of Pediatric Neurology, Ankara, Turkey.
⁵ Marmara University, School of Medicine, Department of Pediatrics, Division of Pediatric Pulmonology, Istanbul, Turkey.

PMID: 37559530
PMCID: PMC10692934 (available on 2024-12-01)
DOI: 10.5664/jcsm.10760

Abstract

Study objectives: To determine the differences in sleep patterns between preterm infants who received caffeine and those who did not and to evaluate the effects of caffeine therapy on early neurodevelopment. Secondarily, actigraphy and polysomnography were compared to evaluate the sleep of preterm infants.

Methods: Twenty-eight preterm infants ages 28-34 weeks admitted to a single-center Level III neonatal intensive care unit between May 2020 and May 2021 were included. Sleep was assessed by actigraphy for 72 hours with Respironics Mini-Mitter® Actiwatch-2 and Brief Infant Sleep Questionnaire at 6 months corrected age. On the first day of actigraphy, infants underwent polysomnography between 10:00 am and 3:00 pm. Neurodevelopment was evaluated by the Bayley Scales of Infant and Toddler Development-III, the Ages & Stages Questionnaire, and the Hammersmith Infant Neurological Examination.

Results: There were no significant differences in sleep parameters measured by actigraphy, the Brief Infant Sleep Questionnaire, and polysomnography between infants in the caffeine group (n = 12) and no-caffeine group (n = 16). Sensitivity (91.07%) and agreement rate (77.21%) for the actigraphy against polysomnography were highest at the automatic threshold. No significant differences were observed in the neurodevelopment of infants in the caffeine group compared to the no-caffeine group.

Conclusions: Sleep parameters and neurodevelopmental outcomes were not different in infants at 6 months of corrected age with regard to caffeine therapy. Actigraphy at the automatic threshold can be used in infants for sleep pattern assessment.

Clinical trial registration: Registry: ClinicalTrials.gov; Name: Influence of Caffeine Therapy in Preterm Infants; URL: https://www.clinicaltrials.gov/ct2/show/NCT04376749; Identifier: NCT04376749.

Citation: Atalah YEY, Barış HE, Akdere SK, et al. Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age. J Clin Sleep Med. 2023;19(12):2075-2085.

Keywords: actigraphy; caffeine; neurodevelopment; polysomnography; preterm; sleep disorder.

Publication types

Clinical Trial

MeSH terms

Apnea
Caffeine* / therapeutic use
Humans
Infant
Infant, Newborn
Infant, Premature*
Polysomnography
Sleep

Substances

Caffeine

Associated data

ClinicalTrials.gov/NCT04376749